Brain OligometastaticOligoLungNCT07389642
Brain Oligometastasis in NSCLC
An observational study of Brain Oligometastatic and Non-small Cell Lung Cancer, run by University Hospital, Bordeaux at 1 site in France.
Trial summary
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Brain Oligometastatic, Non-small Cell Lung Cancer
- What is being tested?
- Standard treatments / multiple strategies
- How many people
- 46 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2025to Mar 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Child, Adult, Older adult
Study population: Patient with NSCLC treated at CHU Bordeaux and Bergonié Institute
Who may be able to join
- Consecutive patients managed at Bordeaux University Hospital
- Non-small-cell lung cancer
- Oligometastatic brain cancer (fewer than 5 lesions at diagnosis)
- Patient over 18 years old
Who cannot join
- Oncogenic addiction EGFR, ALK, ROS1
- Patient with concomitant cancer
- Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Management of Patients With Brain-onset Oligometastatic Non-small-cell Lung Cancer (NSCLC)
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute
Read the detailed description
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.
- Conditions
- Brain Oligometastatic, Non-small Cell Lung Cancer
- Being tested
- Standard treatments / multiple strategies
- Keywords
- Metastatic NSCLC, Brain metastasis, Oligometastasis, Survival
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard treatments / multiple strategiesOther
Standard treatments / multiple strategies
| Study group | Role | What they receive |
|---|---|---|
| Local treatments | Local multimodal treatments (thoracic surgery/radiotherapy + brain surgery/radiotherapy) Receives: Other: Standard treatments / multiple strategies | |
| Systemic treatment | Chemoimmunotherapy combination Receives: Other: Standard treatments / multiple strategies |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression free survival (PFS)
Time from random assignment in a clinical trial to disease progression or death from any cause
Measured: Once, at progression or death from any cause
Secondary outcomes (2)
PFS from the date of the next treatment to disease progression or death from any cause (PFS2)
PFS from the date of the next treatment to disease progression or death from any cause
Measured: Once, at progression or death from any cause
Overall survival (OS)
Time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive
Measured: Once, death from any cause or lost of follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2026
- Study start1 Jan 2025
- Primary completionMar 2026 (estimated)
- Study completionMar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain OligometastaticStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Bordeaux
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07389642
- Sponsor's protocol ID
- CHUBX 2025/058
- Acronym
- OligoLung
- Status last verified
- Jan 2026
- First submitted
- 28 Jan 2026
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Management of Patients With Brain-onset Oligometastatic Non-small-cell Lung Cancer (NSCLC)
- ClinicalTrials.gov ID
- NCT07389642
- Acronym / sponsor ID
- OligoLung / CHUBX 2025/058
- Conditions
- Brain Oligometastatic, Non-small Cell Lung Cancer
- Keywords
- Metastatic NSCLC, Brain metastasis, Oligometastasis, Survival
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 46 participants (actual)
- Lead sponsor
- University Hospital, BordeauxUniversity, hospital or other
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- Mar 2026 (estimated)
- Study completion
- Mar 2026 (estimated)
- First posted
- 5 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute
Detailed description
75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Local treatments | – | Other: Standard treatments / multiple strategiesLocal multimodal treatments (thoracic surgery/radiotherapy + brain surgery/radiotherapy) |
| Systemic treatment | – | Other: Standard treatments / multiple strategiesChemoimmunotherapy combination |
Who may qualify
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- Patient with NSCLC treated at CHU Bordeaux and Bergonié Institute
Key inclusion criteria (4 listed)
- Consecutive patients managed at Bordeaux University Hospital
- Non-small-cell lung cancer
- Oligometastatic brain cancer (fewer than 5 lesions at diagnosis)
- Patient over 18 years old
Key exclusion criteria (3 listed)
- Oncogenic addiction EGFR, ALK, ROS1
- Patient with concomitant cancer
- Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard treatments / multiple strategiesStandard treatments / multiple strategies | Other | Local treatments, Systemic treatment |
Primary outcome
Progression free survival (PFS)
Time frame: Once, at progression or death from any cause
Time from random assignment in a clinical trial to disease progression or death from any cause
2 secondary outcomes
PFS from the date of the next treatment to disease progression or death from any cause (PFS2)
Time frame: Once, at progression or death from any cause
Overall survival (OS)
Time frame: Once, death from any cause or lost of follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Brain Oligometastatic
Recruiting
Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Metastatic Sarcoma, Radiation Therapy Patient
Recruiting
Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.
Brain Metastasis, Oligoprogression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Brain Oligometastatic and Non-small Cell Lung Cancer, run by University Hospital, Bordeaux at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression free survival (PFS) (time frame: Once, at progression or death from any cause). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2026.